Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation. The better we can predict these patients, the more we can get the right therapy early POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505

The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO

New 2023 @eular_org SLE recommendations Key changes, in response to evidence: - more caution re: steroids - biologics earlier - combo therapy (BEL or CNI/VCS) considered for lupus nephritis #EULAR2023 @RheumNow https://t.co/J3Lp8owRyT

#EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i

Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY